The ReWalk Exoskeletal Walking System for Persons With Paraplegia (VA_ReWalk)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
It is well appreciated that an extreme sedentary lifestyle from paralysis, contributes to many secondary medical problems such as diabetes and insulin resistance, obesity, constipation, poor blood pressure regulation, cardiovascular disease, reduced quality of life, and more. The ReWalk-I exoskeleton walking device permits investigation of the potential benefits of frequent upright posture and walking on many of the secondary consequences of spinal cord injury. The researchers are investigating the ability of persons with paraplegia to learn to stand and walk with the ReWalk-I and the effects of being upright and walking on several of these secondary medical consequences of spinal cord injury.
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | The ReWalk Exoskeletal Walking System for Persons With Paraplegia |
- Percent change from baseline [ Time Frame: ReWalk training at 4 and 12 weeks, and 16-week follow-up ] [ Designated as safety issue: No ]
1. To determine efficacy for mobility defined as the ability to perform the following with the ReWalk-I exoskeletal system, without staff assistance:
- Sit-to-stand,
- Stand-to-sit,
- Standing balance for 1 minutes with both crutches,
- Standing balance for 30 seconds with one crutch,
- Ten meter walk in ≤2 minutes,
- Walk ≥30 meters in 6-minutes, and
- Ascend, turn around and descend 4 stairs in 5 minutes.
- Percent change from baseline [ Time Frame: ReWalk training at 4 and 16 weeks, and 16-week follow-up ] [ Designated as safety issue: No ]Sitting and standing balance skills, bowel function, bladder function by survey, muscle spasms by survey, quality of life by survey, resting and exercise energy expenditure, body composition, and neurological tests. Additional mobility training will be observed for a timed-up-and-go (TUG) and a mild obstacle course (incline, decline, carpeting, step, simulated curb, walking in a figure 8)
| Estimated Enrollment: | 40 |
| Study Start Date: | February 2011 |
| Estimated Study Completion Date: | April 2014 |
| Estimated Primary Completion Date: | May 2013 (Final data collection date for primary outcome measure) |
Potential participants will be pre-screened with the inclusion criteria for eligibility. The informed consent process will begin for those participants who have been determined to meet the inclusion criteria. After the potential participant's signed consent has been provided, further evaluations for eligibility will be performed (e.g., there are several medical and physical exclusion criteria). Those potential participants who meet both the inclusion and exclusion criteria will be eligible to enroll into the ReWalk-I study. Baseline evaluations and personalized measurements for fitting to the ReWalk-I will be performed over one week, before the training sessions begin. The ReWalk sessions will consist of a Learning Phase (12 sessions in 4 weeks) and a Training Phase (18 sessions in 6 weeks). These times may vary by each participant's ReWalk learning curve. Training will begin with sit-to-stand, stand-to-sit, and standing balance activities. Progression to walking will occur as skills advance. Each session will be an average 50 minutes, with 3 sessions per week. The skills to be learned include 1) sit-to-stand, 2) stand-to-sit, 3) 2-arm standing balance, 4) 1-arm standing balance, 5) walking, and 6) stair climbing. The study evaluations will be repeated after the Learning Phase, after the Training Phase and 1-month post training follow-up.
Eligibility| Ages Eligible for Study: | 18 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
- Do you have paraplegia?
- Is your SCI greater than 6 months?
- Are you between the ages of 18 to 65y?
- Is your height between 63 and 75 inches?
- Do you weigh less than 220 pounds?
- Are you legally able to sign for your own consent?
Persons who answer "no" to any of the above questions will not be eligible for the study
Inclusion Criteria:
- Males or females with AIS A or B paraplegia
- Duration of SCI >6 months
- Ages 18 to 65 y
- Height 160 to 190cm (63-75in or 5'3" to 6'3")
- Weight <100kg (<220 lb)
- Ability to give informed consent
Exclusion Criteria:
Diagnosis of neurological injury other than SCI including:
- Multiple sclerosis (MS)
- Stroke
- Cerebral Palsy (CP)
- Amyotrophic lateral sclerosis (ALS)
- Traumatic Brain injury (TBI)
- Spina bifida
- Parkinson's disease (PD)
- Other neurological condition that the study physician considers in his/her clinical judgment to be exclusionary
- Severe concurrent medical disease, illness or condition
- Recent lower extremity fracture within the past 2 years;
- DXA results indicating a t-score below -3.0 and knee BMD <0.70 gm/cm2
- Systemic or peripheral infection
- Atherosclerosis, congestive heart failure, or history of myocardial infarction
- Trunk and/or lower extremity pressure ulcers;
- Other illness, that the study physician considers in his/her clinical judgment to be exclusionary
- Severe spasticity (defined by an Ashworth score of >4.0 or clinical impression of the study physician or physical therapist)
- Significant contractures defined as flexion contracture limited to 35º at the hip and 20º at the knee;
- Diagnosis of heterotrophic ossification of the lower extremities;
- Femoral neck or the total proximal femur bone mineral density T-scores < -3.0
- Psychopathology documentation in the medical record or history of that may conflict with study objectives
- Hypertension (SBP>140, DBP>90)
- Pregnancy and/or lactating females
Contacts and Locations| United States, New York | |
| James J. Peters Veterans Affairs Medical Center; Center of Excellence for the Major Consequences of SCI. | Recruiting |
| Bronx, New York, United States, 10468 | |
| Contact: Pierre K Asselin, MSBioMedEng 718-584-9000 ext 3124 pierre.asselin@va.gov | |
| Contact: Drew Fineberg, BSBioMedEng 718-584-9000 ext 3130 drew.fineberg@va.gov | |
| Principal Investigator: Ann M Spungen, EdD | |
| Principal Investigator: | Ann M Spungen, EdD | Bronx JJPVAMC CoE 7A-13 |
More Information
Additional Information:
No publications provided
| Responsible Party: | Ann M. Spungen, EdD, Associate Director of CoE / Health Science Specialist, James J. Peters Veterans Affairs Medical Center |
| ClinicalTrials.gov Identifier: | NCT01454570 History of Changes |
| Other Study ID Numbers: | JJPVAMC: SPU-09-11, Protocol#: SPU-09-11 |
| Study First Received: | September 14, 2011 |
| Last Updated: | October 18, 2011 |
| Health Authority: | United States: Institutional Review Board United States: Federal Government |
Keywords provided by James J. Peters Veterans Affairs Medical Center:
|
exoskeleton walking system paraplegia paralysis |
Additional relevant MeSH terms:
|
Paraplegia Paralysis Neurologic Manifestations Nervous System Diseases Signs and Symptoms |
ClinicalTrials.gov processed this record on May 16, 2013